Vertex Pharmaceuticals Inc (VRTX)

118.44
1.70 1.50
NASDAQ : Health Care
Prev Close 116.70
Open 117.66
Day Low/High 117.61 / 118.79
52 Wk Low/High 75.90 / 143.45
Volume 249.73K
Avg Volume 1.87M
Exchange NASDAQ
Shares Outstanding 248.44M
Market Cap 29.13B
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Did Corbus Investors Get Thrown Off by a Red Herring?

Did Corbus Investors Get Thrown Off by a Red Herring?

Investors ran for the exits after analysts pointed out that glowing Phase 2 study results for Corbus actually weren't that great. But a better story lies behind this biotech play.

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.

Cramer: Stay the Course, but Keep Cash Handy

Cramer: Stay the Course, but Keep Cash Handy

It's pretty normal to have profit-taking after such a strong first quarter.

Here Are Some of the Top Health Care Stocks in the First Quarter

Here Are Some of the Top Health Care Stocks in the First Quarter

Illumina, Centene, Community Health, Incyte and Vertex were among the healthcare stocks that did well in the first quarter.

Corbus Pharma Drug Shows No Clinical Benefit for Cystic Fibrosis Patients

Corbus Pharma Drug Shows No Clinical Benefit for Cystic Fibrosis Patients

Corbus Pharmaceuticals waves a sea of hands in front of investors' eyes Thursday to obscure dismal results from another mid-stage study of its experimental anti-inflammatory drug anabasum.

Closing Bell: Barclays Bets on Alphabet Growth; Dow Falls, S&P 500 and Nasdaq Rise

Closing Bell: Barclays Bets on Alphabet Growth; Dow Falls, S&P 500 and Nasdaq Rise

A rally in crude oil gave rise to the energy sector in a mixed day of trading.

Crude Rally Boosts Energy Stocks, S&P 500 Inches Higher

Crude Rally Boosts Energy Stocks, S&P 500 Inches Higher

The S&P 500 inches higher in mixed trading Wednesday as a rally in crude helps the energy sector.

Vertex Pharmaceuticals Reaches Upside Price Target

Vertex Pharmaceuticals Reaches Upside Price Target

Base building pays off.

Dow Under Pressure, Nasdaq Rises on Gains in Amazon, Google

Dow Under Pressure, Nasdaq Rises on Gains in Amazon, Google

Stocks are mixed on Wednesday as financials retreat again while tech names move higher.

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Biotech Premarket Movers: Vertex, Sangamo, Depomed

Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket trading on Wednesday.

Stock Futures Edge Higher as U.K. Invokes Article 50 in First Step of Brexit

Stock Futures Edge Higher as U.K. Invokes Article 50 in First Step of Brexit

Stock futures edge higher on Wednesday as markets await the United Kingdom taking the first step to formally remove itself from the European Union.

Analysts' Actions -- Facebook, Amazon, Alphabet, Twitter and More

Analysts' Actions -- Facebook, Amazon, Alphabet, Twitter and More

Here are Wednesday's top research calls, including a downgrade of Twitter and new coverage of Facebook, Amazon and Alphabet.

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex Pharma Shares Higher on Impressive Trial Results for New Cystic Fibrosis Drug

Vertex to seek marketing approval for new 'teza/iva' combination therapy for cystic fibrosis patients.

Why Concert Pharmaceuticals Is Music to Investors' Ears

Why Concert Pharmaceuticals Is Music to Investors' Ears

This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.

What You Must Know About Cystic Fibrosis Drug CTP-656

What You Must Know About Cystic Fibrosis Drug CTP-656

Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.

Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma

Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma

The convenience of a once-daily version of Kalydeco is important to Vertex because it has the potential to simplify dosing of combination regimens the company has in development.

Vertex To Acquire CTP-656 From Concert Pharmaceuticals For The Treatment Of Cystic Fibrosis

Vertex To Acquire CTP-656 From Concert Pharmaceuticals For The Treatment Of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE).

Vertex To Present At The Cowen Healthcare Conference On March 6

Vertex To Present At The Cowen Healthcare Conference On March 6

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Monday, March 6 th at 2:00 p.

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Jana Partners are placing three members on Tiffany's board.

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Unlike Silicon Valley, Biopharma's Top Execs React to Trump Migration Ban With Universal Silence

Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Premarket Biotech Movers: Neurocrine Biosciences, Aralez Pharmaceuticals, Qiagen

Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.

Vertex Reports Full-Year And Fourth-Quarter 2016 Financial Results

Vertex Reports Full-Year And Fourth-Quarter 2016 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full-year and quarter-ended December 31, 2016.

Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research And Development Programs From Vertex

Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research And Development Programs From Vertex

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four promising...

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.

Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business

Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business

Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.

Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis

Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis

Vertex Pharmaceuticals is often mentioned as a takeover target, but the company is evaluating potential acquisitions and partnerships of its own to diversify beyond cystic fibrosis.

Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected

Vertex Pharmaceuticals Sees Sales of Cystic Fibrosis Drug Lower Than Expected

Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.

Vertex View into Cystic Fibrosis Sales Growth Still Limited by European Reimbursement

Vertex View into Cystic Fibrosis Sales Growth Still Limited by European Reimbursement

Results from two studies of next-generation "correctors" for cystic fibrosis, expected in the second half of 2017, will be stock-moving events.